Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. Summary
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
Real-time Quote. Real-time Euronext Paris - 07/23 11:35:06 am
11.93 EUR   -0.08%
07/20European ADRs Up 0.5% Tuesday
MT
07/15CALYXT, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
07/13European ADRs Move Lower in Tuesday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
11.64(c) 11.41(c) 12.02(c) 11.94(c) 11.93(c) Last
60 715 41 040 59 504 57 637 59 851 Volume
-1.52% -1.98% +5.35% -0.67% -0.08% Change
More quotes
Estimated financial data (e)
Sales 2021 66,8 M 78,7 M 78,7 M
Net income 2021 -77,8 M -91,5 M -91,5 M
Net Debt 2021 - - -
P/E ratio 2021 -5,14x
Yield 2021 -
Sales 2022 59,2 M 69,7 M 69,7 M
Net income 2022 -94,3 M -111 M -111 M
Net cash position 2022 49,0  57,7  57,7 
P/E ratio 2022 -6,90x
Yield 2022 -
Capitalization 542 M 638 M 638 M
Capi. / Sales 2021 8,11x
EV / Sales 2022 9,16x
Nbr of Employees 277
Free-Float 89,1%
More Financials
Company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting... 
More about the company
Ratings of Cellectis S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about CELLECTIS S.A.
07/20European ADRs Up 0.5% Tuesday
MT
07/15CALYXT, INC. : Change in Directors or Principal Officers, Financial Statements a..
AQ
07/13European ADRs Move Lower in Tuesday Trading
MT
07/12European ADRs Move Higher in Monday Trading
MT
07/09European ADRs Move Sharply Higher in Friday Trading
MT
07/02European ADRs Move Lower in Friday Trading
MT
06/30CELLECTIS S.A. : Monthly statement on outstanding equity shares and voting right..
CO
06/28European ADRs Down Monday as Ryanair, Carnival, Shell Drop
MT
06/15CELLECTIS : ' Innovation Days event highlighted New Product Development New Geno..
AQ
06/14CELLECTIS S A : ' Innovation Days event highlighted New Product Development, New..
PU
06/14CELLECTIS S A : ' Innovation Days event highlighted New Product Development,  Ne..
PU
06/14Cellectis' Innovation Days event highlighted New Product Development, New Gen..
GL
06/14Cellectis S.A. Announces New Product Candidate Pipeline, and Manufacturing an..
CI
06/10CELLECTIS S A : Corporate Presentation - June 2021
PU
06/07CELLECTIS S A : Corporate Presentation - June 2021
PU
More news
News in other languages on CELLECTIS S.A.
06/15CELLECTIS : un point en matière d'innovation bien accueilli
06/14CELLECTIS S A : A l'occasion des Innovation Days, Cellectis dévoile ses nouveaux..
06/09Gecina signe un nouveau bail de 9 ans au sein de l'immeuble Biopark à Paris
06/02CELLECTIS S A : Résultats de l'Assemblée Générale Mixte des Actionnaires de Cell..
06/01CELLECTIS S A : General Assembly - Vote Results - June 1, 2021
More news
Analyst Recommendations on CELLECTIS S.A.
More recommendations
Chart CELLECTIS S.A.
Duration : Period :
Cellectis S.A. Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 11,93 €
Average target price 22,25 €
Spread / Average Target 86,5%
EPS Revisions
Managers and Directors
André Choulika Chief Executive Officer & Director
Eric Dutang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Francisco J. Esteva Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
CELLECTIS S.A.-51.11%704
MODERNA, INC.233.90%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.39.02%47 022
CELLTRION, INC.-25.21%32 170
SEAGEN INC.-16.87%28 525